Targeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells

Citations Over TimeTop 10% of 2013 papers

Abstract

The acquisition of endocrine resistance is a common obstacle in endocrine therapy of patients with oestrogen receptor-α (ERα)-positive breast tumours. We previously demonstrated that the BIG3-PHB2 complex has a crucial role in the modulation of oestrogen/ERα signalling in breast cancer cells. Here we report a cell-permeable peptide inhibitor, called ERAP, that regulates multiple ERα-signalling pathways associated with tamoxifen resistance in breast cancer cells by inhibiting the interaction between BIG3 and PHB2. Intrinsic PHB2 released from BIG3 by ERAP directly binds to both nuclear- and membrane-associated ERα, which leads to the inhibition of multiple ERα-signalling pathways, including genomic and non-genomic ERα activation and ERα phosphorylation, and the growth of ERα-positive breast cancer cells both in vitro and in vivo. More importantly, ERAP treatment suppresses tamoxifen resistance and enhances tamoxifen responsiveness in ERα-positive breast cancer cells. These findings suggest inhibiting the interaction between BIG3 and PHB2 may be a new therapeutic strategy for the treatment of luminal-type breast cancer.

Related Papers

• → Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide(2012)34 cited
• → Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats(1994)55 cited
• → Sensitivity and insensitivity of breast cancer to tamoxifen(1990)19 cited
• → Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer(1993)11 cited
• → Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance(1994)4 cited